Patents by Inventor Patrick Y. Lu

Patrick Y. Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220333108
    Abstract: Compositions and methods are provided for silencing the Sulf2 and/or GPC3 genes in vivo. Potent siRNA sequences are provided that silence regions of the Sulf2 and GPC3 genes that are identical in human, mice and non-human primates. Combinations of siRNAs also are provided that result in additivity or synergy with silencing of Sulf2 and/or GPC3. Silencing SULF2+TGF?1 showed a dramatic effect against cancer growth in vitro and in vivo.
    Type: Application
    Filed: April 1, 2022
    Publication date: October 20, 2022
    Inventors: David EVANS, John XU, Patrick Y. LU, Vera SIMONENKO
  • Publication number: 20220282258
    Abstract: Compositions containing an anti-TGF-? siRNA molecule and an anti-PDL1 siRNA molecule are provided. Methods of using these compositions to treat cancer also are provided.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 8, 2022
    Inventors: David M. EVANS, Patrick Y. LU
  • Publication number: 20220145301
    Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoA) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
    Type: Application
    Filed: July 12, 2021
    Publication date: May 12, 2022
    Inventors: Patrick Y. LU, Vera SIMONENKO, Yibin CAI, John XU, David EVANS
  • Publication number: 20220054645
    Abstract: The invention relates to the targeted delivery of therapeutic molecules to organs, tissues, and cells of humans and other mammals. The invention is directed to a chemical construct for delivering such therapeutic molecules and to methods of making and using the constructs.
    Type: Application
    Filed: June 28, 2021
    Publication date: February 24, 2022
    Inventors: Xiaoyong LU, David M. EVANS, Patrick Y. LU, Alan LU, Jon XU, Peter Zhang
  • Publication number: 20220040292
    Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
    Type: Application
    Filed: February 8, 2021
    Publication date: February 10, 2022
    Inventors: Shenggao TANG, Dong SHEN, Chun LU, Ziyang HE, Jiaxi HE, Patrick Y. LU
  • Publication number: 20210324384
    Abstract: The present invention provides certain pharmaceutical molecules and compositions and methods of using them to treat cancer. The molecules are small interfering RNA (siRNA) molecules that inhibit TGF-beta 1 and Cox2 in humans and other mammals, which are used alone or in combination with immune checkpoint inhibitors, to treat cancer.
    Type: Application
    Filed: June 28, 2021
    Publication date: October 21, 2021
    Inventors: David M. EVANS, Patrick Y. LU
  • Publication number: 20210246448
    Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.
    Type: Application
    Filed: January 25, 2021
    Publication date: August 12, 2021
    Inventors: Danny TANG, Xueping CHEN, Patrick Y. LU, Vera SIMONENKO, David EVANS, John XU, Deling WANG, Alan LU
  • Publication number: 20210214726
    Abstract: Peptide docking vehicle compositions containing a therapeutic compound, such as an siRNA molecule, and a targeting ligand are provided, together with methods for their preparation and use. The compositions and methods allow targeted cell/tissue delivery of the therapeutic compound to a subject by linking a targeting ligand to the compound to provide enhanced therapeutic benefit. The subject may be an animal or a human.
    Type: Application
    Filed: December 7, 2020
    Publication date: July 15, 2021
    Inventors: Xiaoyong LU, Patrick Y. LU, David M. EVANS
  • Patent number: 11058779
    Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: July 13, 2021
    Assignee: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, Vera Simonenko, Yibin Cai, John Xu, David Evans
  • Publication number: 20210162067
    Abstract: The present invention provides certain peptides and polypeptides useful in the preparation of nanoparticles for delivering nucleic acids and pharmaceutical drugs to mammalian cells and to humans and other mammals. It further provides methods for making the peptides, polypeptides, and nanoparticles and methods for using the nanoparticles.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 3, 2021
    Inventors: Xiaoyong LU, Patrick Y. LU, Vera SIMONENKO, David M. EVANS
  • Publication number: 20200392507
    Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.
    Type: Application
    Filed: October 30, 2017
    Publication date: December 17, 2020
    Applicant: Sirnaomics, Inc.
    Inventors: John Xu, Patrick Y. Lu, Jia Zhou, Qingfeng Li, Vera Simonenko
  • Publication number: 20200108089
    Abstract: The present invention provides pharmaceutical compositions comprising the chemotherapy drug gemcitabine (GEM) and certain derivatives, a taurocholic acid (TCA) formulation, and a Histidine-Lysine Polymer (HKP) conjugate, for enhancement of RNAi cancer therapeutics.
    Type: Application
    Filed: March 19, 2018
    Publication date: April 9, 2020
    Applicants: Suzhou Sirnaomics Biopharmaceuticals Co., Ltd., Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, Aslam Ansari, Parker J. Guan, John J. Xu, Vera Simonenko, Tom Zhong
  • Patent number: 10195368
    Abstract: A handheld high frequency ultrasonic atomizing device for delivering drugs to whole respiratory tract comprising a shell with an air inlet and a lid with a spray nozzle. A drug cup with a piezoelectric transducer and a hood with a spray outlet are provided within the shell. The components of piezoelectric ceramic transducer are as follows (mass percentage): lead tetraoxide 63.3-68.3%, zirconium dioxide 14.2-15.3%, titanium dioxide 8.1-9.5%, strontium oxide 4.6-5.2%, iron sesquioxide 1.5-1.8%, stannic oxide 1.0-1.4%, manganese dioxide 0.3-1.1%, cerium sesquioxide 0.5-0.8%, columbium pentoxide 0.4-0.8% and zinc oxide 0.3-0.7%. This device is small in size, with low power consumption and lower cost, and is able to produce mist with small particle size. The device can efficiently deliver drug liquid into the whole respiratory tract, especially down to the lower respiratory tract and pulmonary alveoli through carrying drug molecules in mist particles.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 5, 2019
    Assignees: CHANGZHOU ZHENGYUAN MEDICAL TECHNOLOGY CO., LTD., GUANGZHOU NANOTIDES PHARMACEUTICALS CO., LTD.
    Inventors: Cheng Wang, Patrick Y. Lu, Chuntian Lu, Songlin Jiang, Shenggao Tang, Tao Yuan
  • Publication number: 20190030187
    Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
    Type: Application
    Filed: September 7, 2016
    Publication date: January 31, 2019
    Applicant: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, Vera Simonenko, Yibin Cai, John Xu, David Evans
  • Publication number: 20180369273
    Abstract: A pharmaceutical composition, comprises micro RNAs with or without chemical modification, and a carrier suitable for delivery in vivo, the carrier is a branched histidine-lysine polypeptide or modified compound thereof. The pharmaceutical composition is capable of inhibiting the growth of colon cancer by inducing programmed death of cancer cell and further be used for the manufacture of a targeted drug for colorectal cancer treatment.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 27, 2018
    Inventors: Alan Y. Lu, Huanlong Qin, Menghan Liu, Patrick Y Lu
  • Patent number: 9868952
    Abstract: The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle.
    Type: Grant
    Filed: July 7, 2013
    Date of Patent: January 16, 2018
    Assignee: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, David M. Evans, John J. Xu, Alan Y. Lu, Qing Ge
  • Publication number: 20170233742
    Abstract: Disclosed herein are small interfering RNA (siRNA) molecules and pharmaceutical compositions containing them for the prevention and treatment of Ebola virus disease. The present invention provides siRNA molecules that inhibit Ebola virus gene expression, compositions containing the molecules, and methods of using the molecules and compositions to prevent or treat EVD in a subject, such as a human patient.
    Type: Application
    Filed: October 16, 2015
    Publication date: August 17, 2017
    Applicant: Sirnaomics, Inc.
    Inventors: Yibin Cai, Patrick Y. Lu, John J. Xu
  • Patent number: 9642873
    Abstract: The present invention provides compositions and methods for using combinations of TGF?1 and Cox-2 inhibitors and TGF?1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGF?1 and Cox-2 at the same time, resulting in significant less scar formation.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: May 9, 2017
    Assignee: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, Vera Simonenko, David Evans, John J. Xu
  • Patent number: 9506063
    Abstract: The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 29, 2016
    Assignee: Sirnaomics, Inc.
    Inventors: Alan Y. Lu, Patrick Y. Lu, David M. Evans, John J. Xu
  • Patent number: RE46873
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 29, 2018
    Assignee: Sirnaomics, Inc.
    Inventors: Patrick Y. Lu, Ling Li, Vera Simonenko